Incannex Healthcare (IXHL) — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

IXHL · Stock Price

USD 4.80+1.38 (+40.35%)

Market Cap: $66.9M

Historical price data

Overview

Incannex Healthcare is a clinical-stage biotech focused on developing proprietary cannabinoid and psychedelic-based therapies for conditions with high unmet need, including sleep apnea and anxiety disorders. The company has progressed its lead asset, IHL-42X for OSA, into pivotal Phase 2/3 trials and is advancing a psilocybin program for GAD. Its strategy centers on securing intellectual property around novel formulations and treatment protocols to build a valuable clinical pipeline, funded through its dual listing on the ASX and NASDAQ.

Sleep DisordersPsychiatryInflammatory Diseases

Technology Platform

A development and IP platform focused on creating novel, patent-protected formulations and treatment protocols for repurposed cannabinoid and psychedelic compounds with known safety profiles.

Pipeline

3

3 drugs in pipeline1 in Phase 3

Drug	Indication	Stage
IHL-42X Low Dose + IHL-42X High Dose + Placebo + IHL-42X (Op...	Obstructive Sleep Apnea	Phase 2/3
IHL-675A + Cannabidiol + Hydroxychloroquine + Placebo	Rheumatoid Arthritis	Phase 2
IHL42X + Acetazolamide 250 MG + Dronabinol 2.5 MG	Obstructive Sleep Apnea	Phase 1

Opportunities

Positive data from the ongoing pivotal Phase 2/3 trial for IHL-42X in sleep apnea could unlock a multi-billion dollar market with no approved pharmaceutical competitors.

Success in the Phase 2b psilocybin trial for anxiety would position the company in the high-growth psychedelic therapeutics sector, attracting potential partnership deals.

Risk Factors

High risk of clinical trial failure for its lead programs, significant regulatory hurdles for Schedule I substances, and a persistent need to raise capital in a challenging biotech funding environment.

Commercialization of approved controlled-substance therapies also presents unique market access challenges.

Competitive Landscape

Faces competition from both traditional pharma and a crowded field of psychedelic/cannabinoid biotechs. Differentiation hinges on demonstrating superior efficacy in pivotal trials and defending IP around novel treatment protocols rather than novel compounds.

More companies in Small Molecule Drugs →More companies in Australia →